Evidence map›Paper›PMID 39126612›Full record

Trial reportInvestigational new drugs2024

A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants.

Pranav Gupta, Manash Chatterjee, Yeonil Kim, Kathleen Deschamps, Lieselotte Lemoine, Kristien Van Dyck, Catherine Zhou Matthews, Sylvie Rottey, Aubrey Stoch, Eseng Lai

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Investigational new drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pranav GuptaMerck & Co., Inc., Rahway, New Jersey, USA. pranav.gupta@merck.com.
Manash ChatterjeeMerck & Co., Inc., Rahway, New Jersey, USA.
Yeonil KimMerck & Co., Inc., Rahway, New Jersey, USA.
Kathleen DeschampsMerck & Co., Inc., Rahway, New Jersey, USA.
Lieselotte LemoineMSD Europe Belgium SRL, Brussels, Belgium.
Kristien Van DyckMSD Europe Belgium SRL, Brussels, Belgium.
Catherine Zhou MatthewsMerck & Co., Inc., Rahway, New Jersey, USA.
Sylvie RotteyGhent University Hospital, Ghent, Belgium.
Aubrey StochMerck & Co., Inc., Rahway, New Jersey, USA.
Eseng LaiMerck & Co., Inc., Rahway, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 1 first-in-human study evaluated the safety, tolerability, and pharmacokinetics of MK-1088, a novel, small-molecule dual inhibitor of adenosine A

Indexed as

Healthy VolunteersAdultDose-Response Relationship, DrugDouble-Blind MethodFemaleFood-Drug InteractionsHumansMaleMiddle AgedPurinergic P1 Receptor AntagonistsPyrimidinesTriazolesYoung Adult2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-aminePurinergic P1 Receptor AntagonistsPyrimidinesTriazolesA2A receptorsA2B receptorsDual inhibitionMK-1088PharmacokineticsSafety

Identifiers

PMID39126612
PMCPMC11625052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.